Stocktoria
Immix Biopharma, Inc. IMMX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-12-16
Immix Biopharma, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $16.3M | $11.3M | $8.7M | $4.2M | $126,527 | $248,149 |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M | -$453,852 |
| Interest expense | — | — | — | $497 | $179,853 | $101,976 |
| Income tax | $37,724 | $41,037 | $26,415 | $10,268 | $6,013 | $17,547 |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M | -$1.1M |
| EPS (diluted) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | — | — |
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M | -$404,694 |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M | — |
| Cash & equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M | $391,086 |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M | $539,597 |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 | $5.3M |
| Shareholders' equity | $93.8M | $13.3M | $16.4M | $13.2M | $18.0M | -$4.7M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.